Trianni has
the leading chimeric human mouse for generation of fully human antibodies.
Not exact matches
A research team
led by Christine Brown, Ph.D., and a clinical team headed by Behnam Badie, M.D., has received a $ 12.8 million grant from the CIRM to fund a phase 1
chimeric antigen receptor (CAR) T cell trial targeting an aggressive brain cancer called malignant glioma, which includes glioblastoma.
To differentiate between vaccines, three vaccine preparations were simultaneously evaluated, the double - inactivated (formalin and UV) whole virus vaccine (DIV), the rDNA - expressed S protein vaccine (SV), and the previously evaluated
chimeric viral - like particle vaccine (VLP) that had
led to immunopathology with virus challenge [16], [17], [20].
Importantly, stimulation of the crosslinking of CD4ζ
chimeric receptors
led to tyrosine phosphorylation as would be expected for a fully functional
chimeric receptor.
Although the T cells of
chimeric animals responded to alloantigen, the response was similar to that of non-
chimeric control animals, suggesting that these cells did not appear to
lead to deletion of alloreactive T cells.
Dr. Locke participated in the clinical trials that
led to US Food and Drug Administration approval of a novel
chimeric antigen receptor (CAR) T - cell therapy called axicabtagene ciloleucel.
Spontaneous expansion of the CAG repeat stretch in the CAG 140 KI mouse model, which carries a
chimeric mouse / human exon 1 containing around 125 CAG repeats and the human polyproline region inserted in the murine huntingtin gene (Menalled et al., 2003, Hickey et al., 2008), has recently
led to a new KI line that carries around 190 CAG repeats (CAG 190 KI) in a congenic C57Bl / 6J background.